Content Conference Coverage Conferences EASL 2009
Acute Hepatitis C Affects Neurocognitive Functioning in People with HIV
- Details
- Category: Neurocognitive Problems
- Created on Friday, 22 May 2009 13:47
Acute coinfection with hepatitis C virus (HCV) can contribute to neurocognitive impairment in people with HIV, according to a British study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Created on Tuesday, 05 May 2009 13:47
As described in a poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, T. Berg and an international team of colleagues conducted Study 106, comparing the efficacy of tenofovir/emtricitabine combination therapy versus tenofovir alone for the treatment of chronic hepatitis B.
EASL 2009: Does HBV Viral Load Level Predict Development of Liver Fibrosis?
- Details
- Category: HBV Disease Progression
- Created on Friday, 29 May 2009 13:47
Two studies presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen looked at the association between HBV DNA level and development of fibrosis, with findings suggesting that the role of HBV viral load differs for hepatitis B "e" antigen (HBeAg) negative and HBeAg positive individuals.
Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Details
- Category: Experimental HBV Drugs
- Created on Tuesday, 12 May 2009 13:47
An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
- Details
- Category: HCV Treatment
- Created on Monday, 18 May 2009 18:19
Active injection drug users (IDUs) and those receiving opiate substitution can be successfully treated for chronic hepatitis C virus (HCV) infection, according to a French study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
More Articles...
- Researchers Present Data on Investigational Cyclophilin Inhibitors Debio 025 and SCY-635
- EASL 2009: Antiviral Agents with Activity against Both HIV and Hepatitis C Virus
- Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
- Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
- EASL 2009: Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
Web Design and Development by